Collaborative Research to Advance Innovation in Oncology

Collaboration is core to our science and evident in everything we do – from the papers we publish, to the way we work in our labs, to the partnerships we establish across industry and academia worldwide. AstraZeneca is committed to academic collaborations in a very big way.  

With the Partner of Choice Network, AstraZeneca is bringing together nine of the world’s foremost oncology medical centers to apply collective brainpower in expediting research in some of the hardest-to-treat cancers.  Each site brings strong translational research capabilities and a desire to change the clinical paradigm through application of innovative translational science to clinical research. These sites include:

  • Cambridge Cancer Center (UK)
  • Institute Gustave Roussy (France)
  • Johns Hopkins University (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Oregon Health and Science University/Knight Cancer Institute (US)
  • Peter MacCallum Cancer Center (Australia)
  • Princess Margaret Cancer Center (Canada)
  • Universidad de Navarra (Spain)
  • Vall D’ Hebron Institute of Oncology (Spain)

How does this partnership accelerate innovation in the treatment of cancer? First and foremost, the partner of choice network serves as a forum for scientific knowledge-sharing and investigation in real-time. These data and novel findings – and what we learn in clinical trials – won’t just be sitting on the shelf; rather, they’ll be shared among partner institutions to be implemented as best practices for patients.

This partnership also helps AstraZeneca push the boundaries of science to change the practice of medicine, transform the lives of patients living with cancer, and ultimately eliminate cancer as a cause of death.

As part of this network, AstraZeneca is funding clinical and non-clinical research proposals from the investigators within this network, aimed at accelerating novel scientific research and innovative clinical trial design and precision medicine strategies.

Today, there are more choices than ever to treat cancer. Still, more than eight million lives are lost each year to the disease. Working collaboratively with these academic investigators, we have an enormous opportunity to shift the paradigm. As each day hundreds of patients walk through the doors of these nine partnering institutions, seeking and deserving treatments optimally targeted to their disease, this partnership is helping us to accelerate key clinical trials and decrease the time it takes to find the right treatment for the right patient.


Veeva ID: Z4-26361

Date of Prep: August 2020

tags

  • Partnering